Non-conventional analgesics - novel non-peptidic antagonists of bradykinin
4РП — Обучение и мобилност на изследователи
- Период
- 1997-02-16 → 2000-02-15
- Финансиране от ЕС
- —
- Участници
- 2
- Схема
- RGI
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Нови непептидни вещества се разработват, за да блокират действието на брадикинина – протеин в тялото, който предизвиква силна болка. Те са важни, защото се стремят да бъдат по-евтини и по-лесни за прием чрез устата от сегашните лекарства.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Research objectives and content The aims of this project are the design and synthesis of new non-conventional analgesics. Bradykinin, a peptide of nine aminoacid residues, is the most potent of the endogenous algogenic substances. Thus, antagonist of bradykinin have a great interest in the treatment and prevention of pain. Since peptidic antagonists are expensive and non-active orally, there is a great interest in the development I of non-peptidic antagonists. The non-peptidic antagonists known until now will be theoretically studied to develop the basic pharmacophore. Then, new derivatives will be design to fullfil that pharmacophore and those derivatives l more interesting will be synthesized and characterized. Subsequently, the analgesic activity will be | evaluated by an experienced group from the Faculty of Medicine of the U. Complutense of Madrid (Spain). In a feed-back process the biological results will be incorporated into the design and synthesis steps to improve the analgesic response. Training contents (objective, benefit and expected impact) Training in molecular modeling and drug design will open new perspectives to the applicant (in a future job search). Moreover, training in synthesis and spectroscopy analysis (nmr, uv, etc.) is fundamental for an organic chemist. Links with industry/industrial relevance (22) Members of the research group have and have had contracts with different pharmaceutical companies.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз